The British Nuclear Medicine Society (BNMS) established a committee in December 2012 to focus on molecular radiotherapy (MRT), the treatment of cancer and benign disease with radiopharmaceuticals.
The remit of the committee is to promote optimisation of practice in the UK, investigation of resource issues to support clinical practice, the support of research and clinical development and education.
The committee is multidisciplinary,
consisting of nuclear medicine physicians, oncologists, physicists, radiopharmacists, technicians, radiographers and nurses, and will comprise a number of working groups.
The Chair of the BNMS Molecular Radiotherapy Committee is Dr Glenn Flux.
Dr Glenn Flux
Royal Marsden NHS Foundation Trust